       Document 0284
 DOCN  M94A0284
 TI    Enzyme immunoassay using native envelope glycoprotein (gp160) for
       detection of human immunodeficiency virus type 1 antibodies.
 DT    9412
 AU    Nair BC; Ford G; Kalyanaraman VS; Zafari M; Fang C; Sarngadharan MG;
       Advanced BioScience Laboratories, Inc., Kensington, Maryland; 20895.
 SO    J Clin Microbiol. 1994 Jun;32(6):1449-56. Unique Identifier : AIDSLINE
       MED/94358112
 AB    An enzyme immunoassay using the purified native gp160 for the detection
       of human immunodeficiency virus type 1 (HIV-1) antibody was developed.
       This assay was determined to be highly specific, since (i) 157 serum
       samples that were confirmed negative by Western blot (immunoblot) (WB)
       were negative, (ii) 41 serum samples from populations with medical
       conditions that might cause nonspecific assay reactivity were all
       negative, and (iii) all 15 serum samples that showed false-positive
       reactions in one or more commercial HIV-1 screening tests were negative.
       The assay gave 100% specificity with a randomly selected and unlinked
       panel of 1,000 serum samples from healthy blood donors. The sensitivity
       of the assay was assessed by testing 238 samples confirmed as HIV-1
       antibody positive by a standardized WB assay. All 238 serum samples
       (100%) were reactive in the native gp160 assay. In a dilution panel of
       14 weakly WB-positive serum samples, 7 samples reacted two-to fivefold
       more strongly in the gp160 assay than in a virus lysate-based assay; the
       remaining 7 samples gave comparable reactivities in the two tests. The
       reactivities of 13 of these 14 serum samples in the gp160 assay were
       higher than in a commercial enzyme immunoassay that uses a recombinant
       envelope protein as the antigen. The native gp160 assay was more
       sensitive to identify seroconversion. In a well-characterized panel of
       sequential blood samples from a seroconverter, the new assay detected
       antibodies at least one sample ahead of the other commercial assays
       tested.
 DE    AIDS Serodiagnosis/*METHODS  Blotting, Western  Cells, Cultured
       Comparative Study  Gene Products, env/*IMMUNOLOGY/ISOLATION & PURIF
       Human  HIV Antibodies/*BLOOD  HIV Antigens/*IMMUNOLOGY  HIV Core Protein
       p24/IMMUNOLOGY  HIV Envelope Protein gp120/IMMUNOLOGY  HIV
       Seropositivity/DIAGNOSIS  HIV-1/*IMMUNOLOGY  *Immunoenzyme Techniques
       Protein Precursors/*IMMUNOLOGY/ISOLATION & PURIF  Sensitivity and
       Specificity  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

